Literature DB >> 20153397

Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays.

James M Mathew1, Gaetano Ciancio, George W Burke, Rolando O Garcia-Morales, Anne Rosen, Edward Wang, Carmen I Gomez, Bonnie B Blomberg, Laphalle Fuller, Violet Esquenazi, Camillo Ricordi, Joshua Miller.   

Abstract

Ex vivo identification of donor-specific unresponsiveness in organ transplant recipients is important for immunosuppression (IS) minimization. We tested three groups of stable living, related-donor kidney transplant patients up to 11 years postoperatively, i.e., 20 haploidenticals with donor bone marrow cell (DBMC) infusions, eight noninfused haploidentical controls (haplo controls), and 11 HLA-identical controls (HLA-id), using multiple ex vivo immune assays. We observed that no patients developed donor-specific antibodies. The majority showed donor-specific CTL unresponsiveness from year 1 onward. Thirteen of 20 DBMC recipients became specifically donor MLR nonreactive. Depletion of donor cells in DBMC recipients still MLR reactive increased donor-specific reactivity by 75% +/- 36% (p = 0.04). Adding them back in low concentration caused antigen specific inhibition. The frequencies of ELISPOT granzyme-B and interferon-gamma-producing cells somewhat paralleled the CTL and MLR responses. In the trans vivo DTH, 14 of 19 DBMC recipients demonstrated donor-specific unresponsiveness and 16 of 19 showed "linked suppression," vs none of eight and one of eight haplo controls and vs six of 10 and one of 10 HLA-ids, respectively. Most importantly, when all six assays were performed simultaneously, 10 of 18 DBMC, five of 10 HLA-ids, and no haplo controls were specifically donor unresponsive long term. We propose that a cluster analysis combining these assays will reveal tolerant recipients in whom IS minimization may safely be tested. This appears to have occurred in many DBMC-infused recipients. Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153397      PMCID: PMC2874115          DOI: 10.1016/j.humimm.2010.02.008

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  36 in total

Review 1.  The human bone marrow as an immunoregulatory organ.

Authors:  J Miller; J Mathew; R Garcia-Morales; K E Zucker; M Carreno; Y Jin; L Fuller; G W Burke; G Ciancio; A G Tzakis; C Ricordi; L Olson; A Rosen; D Roth; V Esquenazi
Journal:  Transplantation       Date:  1999-10-27       Impact factor: 4.939

2.  Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses.

Authors:  J M Mathew; R Garcia-Morales; L Fuller; A Rosen; G Ciancio; G W Burke; M Carreno; D Temple; A G Tzakis; C Ricordi; J Miller; V Esquenazi
Journal:  Transplantation       Date:  2000-12-27       Impact factor: 4.939

3.  Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis.

Authors:  W J Burlingham; E Jankowska-Gan; A VanBuskirk; C G Orosz; J H Lee; S Kusaka
Journal:  Hum Immunol       Date:  2000-12       Impact factor: 2.850

4.  Tumor necrosis factor-alpha and tumor growth factor-beta1 genotype: partial association with intragraft gene expression in two cases of long-term peripheral tolerance to a kidney transplant.

Authors:  W J Burlingham; P J O'Connell; L M Jacobson; B N Becker; A D Kirk; V Pravica; I V Hutchinson
Journal:  Transplantation       Date:  2000-04-15       Impact factor: 4.939

5.  Human allograft acceptance is associated with immune regulation.

Authors:  A M VanBuskirk; W J Burlingham; E Jankowska-Gan; T Chin; S Kusaka; F Geissler; R P Pelletier; C G Orosz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

6.  Six-year clinical effect of donor bone marrow infusions in renal transplant patients.

Authors:  G Ciancio; J Miller; R O Garcia-Morales; M Carreno; G W Burke; D Roth; W Kupin; A G Tzakis; C Ricordi; A Rosen; L Fuller; V Esquenazi
Journal:  Transplantation       Date:  2001-04-15       Impact factor: 4.939

7.  Tolerance and chimerism after renal and hematopoietic-cell transplantation.

Authors:  John D Scandling; Stephan Busque; Sussan Dejbakhsh-Jones; Claudia Benike; Maria T Millan; Judith A Shizuru; Richard T Hoppe; Robert Lowsky; Edgar G Engleman; Samuel Strober
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

8.  Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients.

Authors:  Gaetano Ciancio; George W Burke; Rolando Garcia-Morales; Kiliana Suzart; Anne Rosen; Camillo Ricordi; Norma S Kenyon; James M Mathew; Andreas G Tzakis; Violet Esquenazi; Joshua Miller
Journal:  Transplantation       Date:  2002-08-27       Impact factor: 4.939

9.  Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool.

Authors:  Britta S Gebauer; Donald E Hricik; Aymen Atallah; Kathryn Bryan; Jocelyn Riley; Magdalena Tary-Lehmann; Neil S Greenspan; Cora Dejelo; Bernhard O Boehm; Bernhard J Hering; Peter S Heeger
Journal:  Am J Transplant       Date:  2002-10       Impact factor: 8.086

10.  A novel micro-cell-mediated lympholytic assay for the evaluation of regulatory cells in human alloreactive CTL responses.

Authors:  James M Mathew; Bonnie Blomberg; Laphalle Fuller; George W Burke; Gaetano Ciancio; Norma Kenyon; Camillo Ricordi; Andreas G Tzakis; Violet Esquenazi; Joshua Miller
Journal:  J Immunol Methods       Date:  2003-01-15       Impact factor: 2.303

View more
  7 in total

1.  Pretransplant immune regulation predicts allograft outcome: bidirectional regulation correlates with excellent renal transplant function in living-related donor-recipient pairs.

Authors:  Ewa Jankowska-Gan; Adam Sheka; Hans W Sollinger; John D Pirsch; R Michael Hofmann; Lynn D Haynes; Michael J Armbrust; Joshua D Mezrich; William J Burlingham
Journal:  Transplantation       Date:  2012-02-15       Impact factor: 4.939

Review 2.  Microchimerism in promoting graft acceptance in clinical transplantation.

Authors:  James M Mathew; Joseph R Leventhal; Joshua Miller
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

3.  A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab.

Authors:  Gaetano Ciancio; Junichiro Sageshima; Edip Akpinar; Jeffrey J Gaynor; Linda Chen; Alberto Zarak; Lois Hanson; Lissett Tueros; Giselle Guerra; Adela Mattiazzi; Warren Kupin; David Roth; Camillo Ricordi; George W Burke
Journal:  Transplantation       Date:  2013-11-15       Impact factor: 4.939

4.  Antithymocyte globulin facilitates alloreactive T-cell apoptosis by means of caspase-3: potential implications for monitoring rejection-free outcomes.

Authors:  Chethan Ashokkumar; Qing Sun; Mylarappa Ningappa; Brandon W Higgs; George Mazariegos; Adriana Zeevi; Rakesh Sindhi
Journal:  Transplantation       Date:  2015-01       Impact factor: 4.939

5.  Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers.

Authors:  J R Leventhal; J M Mathew; D R Salomon; S M Kurian; J J Friedewald; L Gallon; I Konieczna; A R Tambur; J Charette; J Levitsky; C Jie; Y S Kanwar; M M Abecassis; J Miller
Journal:  Am J Transplant       Date:  2015-07-30       Impact factor: 8.086

6.  Requirement of cognate CD4+ T-cell recognition for the regulation of allospecific CTL by human CD4+ CD127- CD25+ FOXP3+ cells generated in MLR.

Authors:  Yuming Yu; Joshua Miller; Joseph R Leventhal; Anat R Tambur; Dhivya Chandrasekaran; Josh Levitsky; Xunrong Luo; James M Mathew
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

7.  Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation.

Authors:  Jennifer R Zitzner; Anat R Tambur
Journal:  Cells       Date:  2012-05-10       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.